News
SGLT2 inhibitor use rising in patients with DKD
August 23, 2021
Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.
News
Apixaban more effective, safer than rivaroxaban for Afib patients
August 23, 2021
Is apixaban more effective and safer than rivaroxaban in patients with atrial fibrillation?
News
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
News
Use of point-of-care ultrasound (POCUS) for heart failure
August 16, 2021
Hospitalist use of POCUS may include guiding procedures, aiding in diagnosis, and assessing effectiveness of treatment.
News
Heparin’s COVID-19 benefit greatest in moderately ill patients
August 13, 2021
A multiplatform trial reported that therapeutic heparin improved outcomes in moderately ill COVID-19 patients but not in critically ill patients.
News
Tachycardia syndrome may be distinct marker for long COVID
August 13, 2021
Post-COVID patients with palpitations or chest pain should undergo a cardiac workup, new research suggests. The data also shed light on potential treatments.
News
Docs fight back after losing hospital privileges, patients, and income
August 10, 2021
Physicians in St. Louis lost their hospital privileges when the hospital entered into an exclusive contract with other physicians. They’re losing patients and money.
News
Myocarditis tied to COVID-19 shots more common than reported?
August 6, 2021
Myocarditis may develop rapidly in younger people, mostly after the second dose, while pericarditis affects older adults after the first or second dose. Both remain rare, new results show.
News
DOACs best aspirin after ventricular ablation: STROKE-VT
August 2, 2021
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
News
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.